Recent developments in adeno-associated virus vector technology.
about
Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancerNeuroanatomy goes viral!Parkinson's disease: gene therapiesBacteriophage-derived vectors for targeted cancer gene therapyGene therapy for human hearing loss: challenges and promisesAdeno-associated virus-mediated microRNA delivery and therapeuticsGene therapy on the moveGene delivery to adipose tissue using transcriptionally targeted rAAV8 vectorsLong-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonatesSialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage diseaseIntracisternal Gtf2i Gene Therapy Ameliorates Deficits in Cognition and Synaptic Plasticity of a Mouse Model of Williams-Beuren SyndromeGlial promoter selectivity following AAV-delivery to the immature brain.Directed evolution of adeno-associated virus for glioma cell transductionTropism-modified AAV vectors overcome barriers to successful cutaneous therapy.Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous.Cationic lipid formulations alter the in vivo tropism of AAV2/9 vector in lungContribution of Intronic miR-338-3p and Its Hosting Gene AATK to Compensatory β-Cell Mass Expansion.High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectorsSubretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice.Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuriaPeptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivoCombined paracrine and endocrine AAV9 mediated expression of hepatocyte growth factor for the treatment of renal fibrosisPrimate models of schizophrenia: future possibilities.Synthetic aptamer-polymer hybrid constructs for programmed drug delivery into specific target cellsMicrofluidic device for stem cell differentiation and localized electroporation of postmitotic neurons.In vitro re-expression of the aryl hydrocarbon receptor (Ahr) in cultured Ahr-deficient mouse antral follicles partially restores the phenotype to that of cultured wild-type mouse follicles.Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer.Gene therapy for red-green colour blindness in adult primates.Clinical review: gene-based therapies for ALI/ARDS: where are we now?Ribosomal DNA integrating rAAV-rDNA vectors allow for stable transgene expression.Inducible, reversible system for the rapid and complete degradation of proteins in mammalian cellsBioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo.Hyperexpressed Netrin-1 Promoted Neural Stem Cells Migration in Mice after Focal Cerebral Ischemia.Telomerase at the intersection of cancer and aging.AAV Vectors Vaccines Against Infectious Diseases.Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells).Adeno-associated viral vectors for mapping, monitoring, and manipulating neural circuits.Targeted gene therapy for the treatment of heart failure.Gene therapy for the neurological manifestations in lysosomal storage disorders.Gene therapy enters the pharma market: the short story of a long journey.
P2860
Q24615809-0E56A037-69A8-475C-82BC-3305ABA54DA6Q26802140-0575B797-D531-462F-B3FF-AD80DC978B70Q26824184-933B277E-B370-4C4B-AFA5-48D25EACA050Q26865726-5A5FB8CC-4EDD-45F4-BC0C-0E3D6F41A067Q26996322-CEDFEDC7-436D-42C2-ABC3-2C1C57C582D7Q27005597-5C9F3836-CDE0-4C57-B1CF-3CAB5B1E5170Q27007012-75D17C3C-0AB0-45E6-BE88-9568C7ABCEDDQ27318007-636050F4-CEE2-4AE2-B93C-54926DA77D13Q27318381-EF9D9CB4-897F-49CA-B763-E509206CB325Q30519560-1D0BE26E-73CD-4D37-ACC0-BC342E11384EQ30736046-9D88B4EE-0DE6-4AC6-9F05-CC610CF51D82Q31120301-08CEA196-C66D-4C46-A4CF-9DDEEE05EDBEQ33484220-92115AD4-4C09-4DBD-8588-43562B987E27Q33587005-7DD62708-6684-482C-ABC8-31255F98A2CDQ33622746-65A3074B-17CC-4088-8053-E7FE8F5839DFQ33622758-C3AF09C0-41C4-4ECB-84F9-6FF193BF35CEQ33631728-D10E7098-2939-4807-B447-1AB5D9177303Q33713361-D629A444-6513-4663-BB5D-B3D6469C680BQ33739804-E2FF5900-24FC-4D14-90D9-70D535C577A4Q33832790-418F3EB4-2C35-4FD3-8E27-B01C01387590Q33995646-E0BB6A2F-7647-42CB-8535-A479364F36EDQ34025091-6514F8E9-C5C8-4A47-9FFD-D421783E3A25Q34090316-A2DB81D2-2FD5-4977-B22B-DAA39CA8FD39Q34408096-5E0CD015-AA98-4B55-A264-3DC6D00A135BQ34608898-E64C3BBA-2BE4-4C4A-9C9C-1AADF2B503EDQ34809103-8BFC59B2-7E06-4B57-AE2D-44D42ED2CDD6Q34994501-37FDE1D1-33D5-4259-BEA4-5C389BDB331FQ35003425-D7BD01F6-FA58-4C7C-A71C-B509CC73656EQ35558172-59CE9EAC-8CED-460D-A37C-8CA264944EDBQ36298655-74BBBF9B-F755-42E0-8150-233780B934E3Q36471246-0E944AD6-F825-4ED9-B0B0-538D8EBFB42BQ37066323-82D035EB-F52E-4F9E-825C-6790FC157B0FQ37297973-452A9D67-4B7B-4155-A5AB-5C0BEE91060BQ37497995-0A7D2D90-471F-412F-846C-622BF758D033Q37498000-204F26C1-2225-4982-B83A-0690104412F4Q37615161-4D13B4E1-E3AE-43AE-AAF4-3B3868AC4897Q37841584-D9543EC5-EB42-4086-A1A8-EC7BA5862A82Q37878086-870621A3-230A-4E37-8C5F-87733EDB859BQ38200599-73346BC4-8287-4F46-89A2-44B89D35607AQ38566097-B2D214B2-604C-419A-B020-976C023240FC
P2860
Recent developments in adeno-associated virus vector technology.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Recent developments in adeno-associated virus vector technology.
@ast
Recent developments in adeno-associated virus vector technology.
@en
Recent developments in adeno-associated virus vector technology.
@nl
type
label
Recent developments in adeno-associated virus vector technology.
@ast
Recent developments in adeno-associated virus vector technology.
@en
Recent developments in adeno-associated virus vector technology.
@nl
prefLabel
Recent developments in adeno-associated virus vector technology.
@ast
Recent developments in adeno-associated virus vector technology.
@en
Recent developments in adeno-associated virus vector technology.
@nl
P2093
P2860
P356
P1476
Recent developments in adeno-associated virus vector technology.
@en
P2093
Hildegard Büning
Luca Perabo
Oliver Coutelle
Sibille Quadt-Humme
P2860
P304
P356
10.1002/JGM.1205
P577
2008-07-01T00:00:00Z